Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Sunho Biologics,Inc. (2898) Stock Price & Analysis

0 Followers

2898 Stock Chart & Stats

HK$6.39HK$0.00(0.00%)
At close: 4:00 PM GMT+8
HK$6.5HK$7HK$7.5Dec 8Dec 19Jan 5Jan 20Jan 29Feb 12Mar 4
Day’s Range
HKD 5.55 - HKD 6.39
52-Week Range
HKD 5.10 - HKD 8.00
Previous Close
HKD 6.39
Volume
N/A
Average Volume (3M)
0
Market Cap
HKD 970.43M
Enterprise Value
HKD 370.01M
Total Cash (Recent Filing)
HKD 441.40M
Total Debt (Recent Filing)
HKD 68.24M
Price to Earnings (P/E)
―
Beta
0.01
Next Earnings
Apr 05, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Relatively low reported debt-to-equity gives the company more financial flexibility to endure prolonged R&D cycles and pursue financing without immediate solvency pressure. Over 2–6 months, limited leverage reduces bankruptcy risk and preserves capacity to raise growth capital if needed.

Early Free Cash Flow Improvement

A modest uptick in free cash flow growth, even from a weak base, indicates the business may be beginning to stabilize cash conversion. If sustained, improving FCF can support working capital, fund late-stage development, and reduce dependence on dilutive financing over the medium term.

Access To Hong Kong Capital Markets

Being listed on HKEX provides structural access to regional and international capital, enhancing options for follow-on financing and strategic partnerships. For a cash‑consuming biotech, this listing bolsters long-term fund-raising flexibility and investor reach versus unlisted peers.

Bears Say

Severe Revenue Collapse

A ~98% revenue decline is a structural red flag: it erodes core cash generation, undermines commercial viability, and limits ability to fund operations and R&D internally. Over several months this magnifies funding needs and raises execution risk for product development and commercialization plans.

Deep Negative Margins And Losses

Persistently negative operating and net margins indicate the business is not yet achieving scalable economics. Continued losses deplete equity, necessitate external capital, and can lead to repeated dilution, making it harder to achieve sustainable profitability without structural changes to the model.

Negative Cash Flow And Prior Negative Equity

Negative operating and free cash flows combined with historical negative equity signal weak solvency and limited balance-sheet resilience. Over the medium term this constrains strategic choices, increases refinancing risk, and can force unfavorable financing or asset sales to bridge funding gaps.

Sunho Biologics,Inc. News

2898 FAQ

What was Sunho Biologics,Inc.’s price range in the past 12 months?
Sunho Biologics,Inc. lowest stock price was HK$5.10 and its highest was HK$8.00 in the past 12 months.
What is Sunho Biologics,Inc.’s market cap?
Sunho Biologics,Inc.’s market cap is HK$970.43M.
When is Sunho Biologics,Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Sunho Biologics,Inc.’s earnings last quarter?
Sunho Biologics,Inc. released its earnings results on Aug 29, 2025. The company reported -HK$0.272 earnings per share for the quarter.
Is Sunho Biologics,Inc. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Sunho Biologics,Inc. pay dividends?
Sunho Biologics,Inc. does not currently pay dividends.
What is Sunho Biologics,Inc.’s EPS estimate?
Sunho Biologics,Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sunho Biologics,Inc. have?
Sunho Biologics,Inc. has 156,666,800 shares outstanding.
What happened to Sunho Biologics,Inc.’s price movement after its last earnings report?
Sunho Biologics,Inc. reported an EPS of -HK$0.272 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sunho Biologics,Inc.?
Currently, no hedge funds are holding shares in HK:2898
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology